FLJ12716 Activators
FLJ12716 Activators encompass a spectrum of chemical compounds that indirectly promote the functional activity of FLJ12716, targeting various cellular signaling mechanisms. Forskolin, for instance, enhances FLJ12716 activity by increasing cAMP levels that activate PKA, which may target proteins within FLJ12716-associated pathways for phosphorylation. Similarly, PMA serves as a PKC activator, potentially enhancing FLJ12716 activity through PKC-mediated phosphorylation events linked to FLJ12716's signaling network. Epigallocatechin gallate, by inhibiting certain kinases, may relieve inhibitory impacts on FLJ12716 signaling. In parallel, the modulation of lipid signaling by sphingosine-1-phosphate can potentiate FLJ12716 activity by affecting cellular responses that FLJ12716 might regulate. Ionomycin, by increasing intracellular calcium, and Thapsigargin, by inhibiting calcium reuptake, both contribute to the activationof calcium-dependent pathways potentially linked to FLJ12716 activity. LY294002 and Wortmannin, as PI3K inhibitors, can enhance FLJ12716 function by attenuating the PI3K/Akt pathway, which might negatively regulate pathways that FLJ12716 is involved in, thereby allowing for an increase in FLJ12716's signaling activity.
Further activation mechanisms of FLJ12716 involve kinase inhibitors such as U0126 and SB203580, which target the MAPK/ERK and p38 MAPK pathways, respectively. By reducing the activity within these pathways, they may create a signaling milieu that favors the activation of pathways where FLJ12716 operates. Genistein's inhibition of tyrosine kinases could also bolster FLJ12716 activity by reducing competing phosphorylation signals. Additionally, staurosporine, despite broadly targeting protein kinases, might selectively augment FLJ12716-associated pathways by alleviating kinase-mediated suppression. Collectively, these FLJ12716 Activators, through targeted alterations in intracellular signaling, facilitate the enhancement of FLJ12716-mediated functions without necessitating an increase in its expression or direct stimulation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin, through the activation of adenylate cyclase, increases intracellular cAMP levels, which can enhance the activity of FLJ12716 by stimulating cAMP-dependent protein kinase A (PKA). PKA phosphorylation can lead to the activation of downstream targets involved in the same signaling pathways as FLJ12716. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which can phosphorylate a variety of proteins within pathways that FLJ12716 might be a part. This action can lead to the enhancement of FLJ12716 through downstream effects that promote signaling cascades in which FLJ12716 is involved. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG inhibits several kinases, which might relieve negative regulation on pathways involving FLJ12716, thus enhancing its activity indirectly by reducing competitive signaling interference. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
S1P binds to its receptors, leading to the activation of intracellular signaling cascades that can enhance the activity of FLJ12716 through modulation of cytoskeletal reorganization and cellular responses in which FLJ12716 might play a role. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin acts as a calcium ionophore, raising intracellular calcium levels and potentially enhancing FLJ12716 activity by activating calcium-dependent signaling pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that by reducing PI3K/Akt pathway activity, can lead to an enhancement of FLJ12716 activity if FLJ12716 is involved in signaling pathways that are negatively regulated by PI3K/Akt. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 inhibits MEK1/2, leading to a downregulation of the MAPK/ERK pathway. This inhibition could indirectly enhance FLJ12716 activity if FLJ12716 functions in a parallel or downstream pathway that is positively regulated when MAPK/ERK signaling is diminished. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK, and by inhibiting this pathway, it may indirectly enhance FLJ12716 activity if FLJ12716 is part of alternate signaling pathways that become more active when p38 MAPK signaling is reduced. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein is a tyrosine kinase inhibitor. By blocking tyrosine kinase activity, it could enhance FLJ12716 activity by reducing competition from tyrosine kinase signaling pathways that might otherwise suppress pathways where FLJ12716 is active. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin inhibits the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA), leading to an increase in cytosolic calcium levels which may enhance FLJ12716 activity through activation of calcium-dependent signaling mechanisms. | ||||||